CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
A091603 | Alliance | A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Adult CIRB - Late Phase Emphasis | Completed |
A011801 | Alliance | The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb | Adult CIRB - Late Phase Emphasis | Available to Open |
A221505 | Alliance | RT Charm: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction | Cancer Prevention and Control CIRB | Available to Open |
A211701 | Alliance | A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort | Cancer Prevention and Control CIRB | Completed |
A081801 | Alliance | Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO | Adult CIRB - Late Phase Emphasis | Available to Open |
A092104 | Alliance | A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
EA9161 | Alliance | A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | Adult CIRB - Late Phase Emphasis | Available to Open |
A021806 | Alliance | A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
A211901 | Alliance | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions | Cancer Prevention and Control CIRB | Available to Open |
EA9171 | Alliance | BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD | Adult CIRB - Late Phase Emphasis | Available to Open |